ARTICLE | Clinical News
recombinant human CC10 (rhCC10) uteroglobin: Began Phase I trial
March 12, 2001 8:00 AM UTC
Claragen Inc., College Park, Md. Product: recombinant human CC10 (rhCC10) uteroglobin Business: Pulmonary Therapeutic category: Immune modulation, Cytokine production Target: Secretory phospholipase ...